Day: April 29, 2025

Vilnius, Lithuania, April 29, 2025 (GLOBE NEWSWIRE) — AB Tewox (the Company) publishes its audited annual consolidated and separate financial statements for 2024 together with Company’s and Group’s annual management report for 2024. Financial results The objective of the Company is to earn a return to shareholders through investments in individual income-generating real estate objects – either under development or already developed – intended for retail or other (commercial and/or residential) purposes in the Baltic Sea Region countries – Lithuania, Latvia, Estonia, Finland, Sweden, Denmark, Poland and Germany. The main financial indicators for the period were:As at 31 December 2024, the Company’s total assets were EUR 75,648 thousand, total equity was EUR 43,448 thousand, and total liabilities were EUR 32,200 thousand. As at...

–Company reports record revenue of $17.6 million for FY 2024, an increase of 21% – –Company to host conference call Today, Tuesday, April 29th at 11am ET/8am PT –NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICESCARLSBAD, Calif., April 29, 2025 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced its financial results for fourth quarter and fiscal year ended December 31, 2024.All figures are in U.S. dollars.Financial and Business HighlightsRecord quarterly and annual revenue – The company recorded its largest ever fourth quarter revenue of $4,702,317 in Q4 2024 compared to Q4 2023 sales of $4,044,234 an improvement of...

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces today it will showcase its ZenaDrone 1000 and IQ series drones as an exhibitor at several prominent upcoming US defense and technology conferences starting this week. These events will be an important opportunity to engage one-on-one with potential customers, key stakeholders, and industry leaders across the US military and government sectors as well as in the mining sector. Conference Details: Modern Day Marine: Recognized as the largest military equipment, systems, services, and technology expositions exclusively targeted to Marine...

– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – TORONTO, April 29, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce initial perioperative data from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA procedure with radical prostatectomy (“RP”) in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. The positive perioperative...

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is issuing the following date correction, which was included in its Operational Results news release issued on April 9, 2025. The April 9, 2025 news release incorrectly indicated the release of Q1-2025 financial results on May 5, 2025. Amerigo will hold its Annual General Meeting of Shareholders on May 5, 2025, and will release Q1-2025 financial results on Wednesday May 7, 2025, at the market open. Amerigo’s quarterly investor conference call will be held on Thursday, May 8, 2025, at 11:00 a.m. Pacific Daylight Time/2:00 p.m. Eastern Daylight Time. Participants can join by visiting https://emportal.ink/4fsXvjM and entering their name and phone number. The conference system will then call the...

Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growth Orders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic revenue guidance of 9.5% – 13.5%WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025. Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We had a strong start to the year with $169 million of revenue, which represented 14% organic non-COVID growth and...

CINCINNATI, April 29, 2025 (GLOBE NEWSWIRE) — Hillman Solutions Corp. (Nasdaq: HLMN) (the “Company” or “Hillman”), a leading provider of hardware products and merchandising solutions, reported financial results for the thirteen weeks ended March 29, 2025. First Quarter 2025 Highlights (Thirteen weeks ended March 29, 2025)Net sales increased 2.6% to $359.3 million compared to $350.3 million in the prior year quarter Net loss totaled $(0.3) million, or $(0.00) per diluted share, compared to $(1.5) million, or $(0.01) per diluted share, in the prior year quarter Adjusted diluted EPS1 was $0.10 per diluted share compared to $0.10 per diluted share in the prior year quarter Adjusted EBITDA1 increased to $54.5 million compared to $52.3 million in the prior year quarter Net cash used by operating activities was $(0.7) million compared...

– ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 – $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 29, 2025 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported first quarter 2025 financial results and recent portfolio execution. “Kiniksa continues to drive...

twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system twiist with Eversense 365 launch expected in Q3 MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) — Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable CGM systems for people with diabetes, today announced their commercial development agreement to integrate Sequel’s twiist Automated Insulin Delivery (AID) System powered by Tidepool with Senseonics’ Eversense 365 CGM. Through this collaboration, the twiist™ Automated Insulin Delivery (AID) System will become the first AID system...

SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) — Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The conference call and webcast will be available via: Webcast: ir.codiagnostics.com on the Events & Webcasts page, or accessible directly here Conference Call: 800-715-9871 (Toll Free) or (646) 307-1963 (Toll) with...